LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250 · Tenax Therapeutics, Inc.
Primary completion dateRecorded edit
− Previous value
2026-06-16
+ Updated value
2026-06-30
TENX
Tenax Therapeutics, Inc.
Company identity checked against sources
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
6Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Oxycyte in Severe Closed Head InjuryNCT00174980 | TENX | Phase 2 | Terminated | 2008-03Actual |
| Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEFNCT03541603 | TENX | Phase 2 | Completed | 2020-04-07Actual |
| Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010 | TENX | Phase 2 | Completed | 2023-04-25Actual |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250 | TENX | Phase 3 | Active not recruiting | 2026-06-30Actual |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT07288398 | TENX | Phase 3 | Recruiting | 2028-06-30Estimated |
| Long-Term Open-Label Extension Study of Oral LevosimendanNCT07436689 | TENX | Phase 3 | Enrolling by invitation | 2029-03Estimated |
Latest recorded trial changes
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250 · Tenax Therapeutics, Inc.
Recruitment statusRecorded edit
− Previous value
Recruiting
+ Updated value
Active not recruiting
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250 · Tenax Therapeutics, Inc.
Primary completion dateRecorded edit
− Previous value
2026-10
+ Updated value
2026-06-16
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250 · Tenax Therapeutics, Inc.
Completion date typeRecorded edit
− Previous value
Estimated
+ Updated value
Actual
Study of Oxycyte in Severe Closed Head Injury
NCT00174980 · Tenax Therapeutics, Inc.
Recruitment statusRecorded edit
− Previous value
Completed
+ Updated value
Terminated
Study of Oxycyte in Severe Closed Head Injury
NCT00174980 · Tenax Therapeutics, Inc.
Primary completion dateRecorded edit
− Previous value
2008-01
+ Updated value
2008-03
Study of Oxycyte in Severe Closed Head Injury
NCT00174980 · Tenax Therapeutics, Inc.
Primary outcomes · main study measuresText edit · unverified significance
− Previous value
measure: Increase in Brain Oxygen Tension levels in severe traumatic head injury patients with GCS score of 3-9
+ Updated value
measure: Brain Dialysate Concentration Data
Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
NCT03624010 · Tenax Therapeutics, Inc.
Primary completion dateRecorded edit
− Previous value
2024-02-01
+ Updated value
2023-04-25
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
NCT03624010 · Tenax Therapeutics, Inc.
Enrollment · participant countRecorded edit
− Previous value
count: 20; type: ACTUAL
+ Updated value
count: 35; type: ACTUAL
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
NCT03624010 · Tenax Therapeutics, Inc.
Primary outcomes · main study measuresText edit · unverified significance
− Previous value
measure: Clinical Safety measured by number of adverse events (AEs )
+ Updated value
measure: Clinical Safety
Check registry source · The saved outcome text may be shortened. Check the source for full wording.